# OnCo record paper-gandara-blood-tmb-atezolizumab-nat-med-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gandara-blood-tmb-atezolizumab-nat-med-2018" ;
  schema:name "Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab"@en ;
  schema:description "Counting mutations in a blood sample rather than in a piece of tumour identified the patients who gained most from one immunotherapy drug, which matters because many patients with advanced lung cancer have no tissue left to test."@en ;
  schema:url <https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-018-0134-3>, <https://pubmed.ncbi.nlm.nih.gov/30082870/> ;
  schema:sameAs <https://doi.org/10.1038/s41591-018-0134-3> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Gandara DR, Paul SM, Kowanetz M, et al." ;
  onco:related <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .